Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Dose Escalating, Open Label, Multi-center, Phase I/IIa Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine.

NCT07185815 is registered in ClinicalTrials.gov with Mapi Pharma Ltd. as lead sponsor.

NCT NCT07185815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07185815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Dose Escalating, Open Label, Multi-center, Phase I/IIa Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine.
Lead sponsor
Mapi Pharma Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 1, 2025
Completion date
June 3, 2027
Enrollment
24 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder, major depressive disorder, schizophrenia